比较PC与GC两种化疗方案一线治疗晚期肺腺癌的临床疗效与安全性

Comparison of clinical effect and safety of first-line chemotherapy with PC and GC in the treatment of advanced lung adenocarcinoma

目的比较培美曲塞二钠联合卡铂与吉西他滨联合卡铂两种不同化疗方案一线治疗晚期肺腺癌的疗效和安全性。方法回顾性分析江苏省宿迁市沭阳县中心医院2015年5月至2018年6月接受一线化疗的80例晚期(ⅢB/Ⅳ期)肺腺癌患者的临床资料,将患者根据不同的化疗方案划分成培美曲塞二钠联合卡铂组(A组)及吉西他滨联合卡铂组(B组)。比较两组患者的临床疗效及安全性。结果两组患者临床疗效比较无统计学差异(P> 0.05)。两组患者在治疗过程中均出现血液学毒性及消化道反应,如白细胞和血小板减少、呕吐、皮疹、肝功能损害、口腔黏膜溃疡、腹泻,但A组患者的不良反应发生率明显少于B组(P <0.05)。结论晚期肺腺癌患者一线应用培美曲塞二钠联合卡铂的疗效略优于吉西他滨联合卡帕,但是培美曲塞二钠联合卡铂治疗所发生的不良反应发生率明显降低。

Objective To compare the effect and safety of PC(pemetrexed disodium combined with carboplatin) and GC(gemcitabine plus carboplatin) in the first-line treatment of advanced lung adenocarcinoma. Methods The clinical data of 80 patients with advanced(IIIB/IV) lung adenocarcinoma who underwent first-line chemotherapy from May 2015 to June2018 were retrosspctively analyzed.Patients were divided into 2 groups according to different chemotherapy regimens including PC group(group A) and GC group(group B). The therapeutic efficacy and safety of the two groups of patients were analyzed. Results There was no significant difference between the two groups in the clinical effect(P>0.05). Both groups had hematologic toxicity and digestive tract reactions during treatment, such as decrease of white blood cells and thrombocyte, vomiting, rash, liver damage, oral mucosal ulcers, diarrhea, but the incidence rates of adverse reactions of group A patients were significantily lower than group B, patients are more acceptable. Conclusion The efficacy of PC in patients with advanced lung adenocarcinoma was slightly better than that in GC, but the incidence rates of adverse reactions of PC were significantly lower than GC.